Scinai Immunotherapeutics Ltd. SCNI

SCNI Company Overview

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is an Israel-based biotechnology company focused on the development and commercialization of inflammation and immunology therapeutics, alongside contract development and manufacturing organization (CDMO) services for biologics. The company operates within the biotechnology, immunotherapy, and biopharmaceutical manufacturing industries. Its activities include early-stage therapeutic research, biologics process development, and manufacturing support for biotechnology companies. Scinai’s revenue generation has historically been limited and primarily associated with research collaborations, grants, and CDMO-related activities while it advances proprietary therapeutic assets.

The company traces its origins to BiondVax Pharmaceuticals Ltd., which was founded to develop influenza vaccines using a recombinant protein platform. Following setbacks in late-stage influenza vaccine development, the company restructured and rebranded as Scinai Immunotherapeutics Ltd. in 2023 to emphasize immunology-focused therapeutics and biologics manufacturing services. Scinai’s positioning centers on combining therapeutic development capabilities with biologics manufacturing infrastructure, particularly for early-stage biotech firms seeking development and production support.